These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34918213)

  • 1. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
    Weeda ER; Muraoka AK; Brock MD; Cannon JM
    Int J Clin Pract; 2021 Sep; 75(9):e14060. PubMed ID: 33527605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.
    d'Aquino AI; Maikawa CL; Nguyen LT; Lu K; Hall IA; Jons CK; Kasse CM; Yan J; Prossnitz AN; Chang E; Baker SW; Hovgaard L; Steensgaard DB; Andersen HB; Simonsen L; Appel EA
    bioRxiv; 2023 Jul; ():. PubMed ID: 36778223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
    Mody R; Manjelievskaia J; Marchlewicz EH; Malik RE; Zimmerman NM; Irwin DE; Yu M
    Clin Ther; 2022 Apr; 44(4):537-554. PubMed ID: 35264311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
    Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
    Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
    Lin J; Lingohr-Smith M; Fan T
    Clinicoecon Outcomes Res; 2017; 9():19-29. PubMed ID: 28053550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
    Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
    Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.
    Durden E; Liang M; Fowler R; Panton UH; Mocevic E
    J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
    Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
    Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
    Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
    Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
    Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
    Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.